Clinical Trial Update: Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update evaluating the combination of pembrolizumab and ibrutinib for unresectable stage III–IV melanoma, sponsored by Mayo Clinic; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Mayo Clinic | Conditions: Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7 | Phase 1 | Status: ACTIVE_NOT_RECRUITING